×
DMARDs improve vascular abnormalities in early RA
https://www.mdedge.com/internalmedicine/article/189951/rheumatoid-arthritis/dmards-improve-vascular-abnormalities-early-ra?channel=39313
Bruce Jancin

Nov 30th, 2018 - CHICAGO – Patients with newly diagnosed RA have subclinical abnormalities in vascular function that are favorably altered after they start to take disease-modifying anti-rheumatic drugs, Maya H. Buch, PhD, said at the annual meeting of the American College of Rheumatology.

Weight loss cuts risk of psoriatic arthritis
https://www.mdedge.com/dermatology/psoriasiscollection/article/189865/psoriatic-arthritis/weight-loss-cuts-risk-psoriatic?channel=281
Bruce Jancin

Nov 29th, 2018 - CHICAGO – Overweight and obese psoriasis patients have it within their power to reduce their risk of developing psoriatic arthritis through weight loss, according to a large British longitudinal study. Bruce Jancin/MDedge News Dr.

Intra-articular Wnt inhibitor for knee OA sails through phase 2
https://www.mdedge.com/familymedicine/article/189810/osteoarthritis/intra-articular-wnt-inhibitor-knee-oa-sails-through?channel=39313
Rheumatology News; Bruce Jancin

Nov 29th, 2018 - CHICAGO – A single intra-articular injection of a novel drug known for now as SMO4690 resulted in statistically significant and clinically meaningful improvements in pain and physical function through 6 months of follow-up in a phase 2b study including 695 patients with moderately to severely symptomatic knee OA, Yusuf Yazici, MD, reported at the annual meeting of the American College of Rheuma.

Knowledge, attitudes about prescription NSAID use for OA varies by ethnicity
https://www.healio.com/rheumatology/osteoarthritis-and-bone-disorders/news/online/%7B6877c5c3-24d4-4a8c-af53-69316ab284cc%7D/knowledge-attitudes-about-prescription-nsaid-use-for-oa-varies-by-ethnicity

Nov 29th, 2018 - Hispanic patients with osteoarthritis were less likely than non-Hispanic white patients to believe that prescription NSAIDs could help or harm them, according to research presented at the ACR/ARHP 2018 Annual Meeting.

Post-Traumatic Osteoarthritis: Managing OA That Develops After Joint Injuries & Reconstructive Surgery
https://www.the-rheumatologist.org/article/post-traumatic-osteoarthritis-managing-oa-that-develops-after-joint-injuries-reconstructive-surgery/
Bernstein, S.

Nov 28th, 2018 - Joint trauma is one of many potential drivers of osteoarthritis disease activity and structural progression. In Post-Traumatic OA: Pathogenesis, Clinical Evolution and Management, a session at the 2018 ACR/ARHP Annual Meeting, experts discussed the effects of sports and other injuries on even young patients’ joints.

Nonsurgical Therapies for Knee OA Pain: From Medications to Bracing to Exercise, What Works & What Doesn’t
https://www.the-rheumatologist.org/article/nonsurgical-therapies-for-knee-oa-pain/
Bernstein, S.

Nov 28th, 2018 - Many nonsurgical therapies are available for knee osteoarthritis pain, but they vary greatly in effectiveness.

Emerging Treatments for OA: New Therapies Target Joint Pain, Not Just Structural Damage
https://www.the-rheumatologist.org/article/emerging-treatments-for-oa/
Bernstein, S.

Nov 28th, 2018 - Are effective treatments for osteoarthritis (OA) on the horizon? In Emerging Treatments for Osteoarthritis at the 2018 ACR/ARHP Annual Meeting, experts discussed potential therapies to address OA structural progression, pain and inflammation.

Glucocorticoid elimination works for 2/3 of RA patients on tocilizumab
https://www.mdedge.com/internalmedicine/article/189590/rheumatoid-arthritis/glucocorticoid-elimination-works-2/3-ra?channel=39313
Mitchel L. Zoler

Nov 27th, 2018 - CHICAGO – Nearly two-thirds of rheumatoid arthritis patients who achieved remission or low disease activity on tocilizumab plus low-dose prednisone were able to taper off prednisone treatment while remaining in at least low disease activity in a multicenter, randomized trial with 259 patients. Mitchel L.

FDA urged to bring rheumatologists into gadolinium safety discussion
https://www.mdedge.com/neurology/article/189524/lupus-connective-tissue-diseases/fda-urged-bring-rheumatologists-gadolinium?channel=39313
Bruce Jancin

Nov 27th, 2018 - CHICAGO – The Food and Drug Administration’s updated safety warning about gadolinium-based contrast agents was dismissed as too little, too late during a postsession discussion at the annual meeting of the American College of Rheumatology. Bruce Jancin/MDedge News Dr.

Bimekizumab improves outcomes among PsA patients
https://www.healio.com/rheumatology/psoriatic-arthritis/news/online/%7B7a7e9093-6643-4a65-b89e-23842acfcae0%7D/bimekizumab-improves-outcomes-among-psa-patients

Nov 27th, 2018 - Bimekizumab, a monoclonal antibody that neutralizes both IL-17A and IL-17F, significantly improved both musculoskeletal and skin outcomes among patients with active psoriatic arthritis, according to phase 2b data presented at the ACR/ARHP 2018 Annual Meeting.

Nerve growth factor antibody cuts OA pain with low AEs
https://www.mdedge.com/clinicianreviews/article/189435/osteoarthritis/nerve-growth-factor-antibody-cuts-oa-pain-low-aes?channel=290
Mitchel L. Zoler

Nov 26th, 2018 - CHICAGO – The nerve growth factor antibody tanezumab met its primary efficacy endpoints for improving pain and physical function in patients with knee or hip OA while also showing a low incidence of the drug’s most concerning adverse effect in the first results from a phase 3 study of a drug in this new class. Mitchel L.

Montreal Cognitive Assessment fares well for rapid, reliable screening in SLE
https://www.mdedge.com/internalmedicine/article/189413/lupus-connective-tissue-diseases/montreal-cognitive-assessment-fares?channel=39313
Bruce Jancin

Nov 26th, 2018 - CHICAGO – The Montreal Cognitive Assessment Test provides persuasive advantages over the standard neuropsychological test battery often recommended in guidelines as a screening tool for cognitive impairment in patients with systemic lupus erythematosus, Nicolas Paez-Venegas, MD, asserted at the annual meeting of the American College of Rheumatology. Related VIDEO: Assessment tool rapidly screen.

Tanezumab safe, effective against OA
https://www.healio.com/rheumatology/osteoarthritis-and-bone-disorders/news/online/%7B1152ead3-8b30-4aa9-835f-f917e85d135c%7D/tanezumab-safe-effective-against-oa

Nov 26th, 2018 - A recent study showed that tanezumab was well-tolerated and superior to placebo in patients with osteoarthritis

MEASURE 3: Higher secukinumab dose safe in patients with AS
https://www.healio.com/rheumatology/spondyloarthropathies/news/online/%7Beee00cc3-2cf9-4a03-8fdc-764631287326%7D/measure-3-higher-secukinumab-dose-safe-in-patients-with-as

Nov 23rd, 2018 - Phase 3 data from the MEASURE 3 trial showed that a 300-mg dose of secukinumab sustained improvements in the signs and symptoms of active ankylosing spondylitis over 3 years without increasing the incidence of adverse events compared with a 150-mg dose.

Gout: new data support treat-to-target approach
https://www.mdedge.com/rheumatology/article/189349/gout/gout-new-data-support-treat-target-approach?channel=216
Bruce Jancin

Nov 21st, 2018 - CHICAGO – Failure to reach the therapeutic target of a serum urate level below 6 mg/dL in gout patients is an independent risk factor for all-cause mortality conferring a 139% increased risk, Fernando Perez-Ruiz, MD, PhD, said at the annual meeting of the American College of Rheumatology. This new finding from a prospective cohort study of 1,193 gout patients constitutes a ringing endorsement t.

Opioid use common before total joint replacement surgery
https://www.healio.com/rheumatology/osteoarthritis-and-bone-disorders/news/online/%7B5cb93c94-3b2b-4d77-b838-e76ad48b144f%7D/opioid-use-common-before-total-joint-replacement-surgery

Nov 21st, 2018 - More than 60% of older patients with moderate-to-severe hip or knee arthritis used opioids before undergoing total joint replacement surgery, according to recent data.

Tofacitinib and TNF inhibitors show similar VTE rates
https://www.mdedge.com/chestphysician/article/189341/rheumatoid-arthritis/tofacitinib-and-tnf-inhibitors-show-similar-vte?channel=48440
Mitchel L. Zoler, MDedge News

Nov 20th, 2018 - CHICAGO – Rheumatoid arthritis patients treated with tofacitinib did not have a significantly increased incidence of hospitalization for venous thromboembolism, compared with patients treated with a tumor necrosis factor (TNF) inhibitor, in a study of more than 50,000 U. S.

Total knee replacement risk soars after arthroscopic surgery for meniscal tear
https://www.mdedge.com/surgery/article/189316/osteoarthritis/total-knee-replacement-risk-soars-after-arthroscopic-surgery?channel=237
Bruce Jancin

Nov 20th, 2018 - CHICAGO – A 5-year follow-up of a major randomized trial comparing methods of meniscal tear management in patients with osteoarthritis showed the risk of total knee replacement was 400% greater in patients who underwent arthroscopic partial meniscectomy than in those who received physical therapy alone, Jeffrey N. Katz, MD, reported at the annual meeting of the American College of Rheumatology.